CA3056685C - Combination therapy for the treatment or prevention of tumours - Google Patents
Combination therapy for the treatment or prevention of tumours Download PDFInfo
- Publication number
- CA3056685C CA3056685C CA3056685A CA3056685A CA3056685C CA 3056685 C CA3056685 C CA 3056685C CA 3056685 A CA3056685 A CA 3056685A CA 3056685 A CA3056685 A CA 3056685A CA 3056685 C CA3056685 C CA 3056685C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- hydrogen
- aryl
- 6alkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901027 | 2017-03-23 | ||
| AU2017901027A AU2017901027A0 (en) | 2017-03-23 | Combination Therapy | |
| PCT/AU2018/050277 WO2018170559A1 (en) | 2017-03-23 | 2018-03-23 | Combination therapy for the treatment or prevention of tumours |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3056685A1 CA3056685A1 (en) | 2018-09-27 |
| CA3056685C true CA3056685C (en) | 2024-01-16 |
Family
ID=63583892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3056685A Active CA3056685C (en) | 2017-03-23 | 2018-03-23 | Combination therapy for the treatment or prevention of tumours |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11213506B2 (enExample) |
| EP (1) | EP3600281B1 (enExample) |
| JP (1) | JP6905075B2 (enExample) |
| KR (1) | KR102228055B1 (enExample) |
| CN (1) | CN110461324A (enExample) |
| AU (1) | AU2018238202C1 (enExample) |
| CA (1) | CA3056685C (enExample) |
| DK (1) | DK3600281T3 (enExample) |
| EA (1) | EA201992220A1 (enExample) |
| ES (1) | ES2953575T3 (enExample) |
| FI (1) | FI3600281T3 (enExample) |
| HR (1) | HRP20230936T1 (enExample) |
| HU (1) | HUE063299T2 (enExample) |
| IL (1) | IL269522B2 (enExample) |
| LT (1) | LT3600281T (enExample) |
| MX (1) | MX391826B (enExample) |
| MY (1) | MY197427A (enExample) |
| PH (1) | PH12019502132A1 (enExample) |
| PL (1) | PL3600281T3 (enExample) |
| PT (1) | PT3600281T (enExample) |
| RS (1) | RS64472B1 (enExample) |
| SG (1) | SG11201907891XA (enExample) |
| SI (1) | SI3600281T1 (enExample) |
| SM (1) | SMT202300272T1 (enExample) |
| UA (1) | UA125614C2 (enExample) |
| WO (1) | WO2018170559A1 (enExample) |
| ZA (1) | ZA201906001B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1971588T3 (da) * | 2005-12-23 | 2012-10-22 | Qbiotics Ltd | Tiglien-3-onderivater |
| KR102160389B1 (ko) | 2013-08-05 | 2020-09-28 | 트위스트 바이오사이언스 코포레이션 | 드 노보 합성된 유전자 라이브러리 |
| CA2975852A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| KR20180050411A (ko) | 2015-09-18 | 2018-05-14 | 트위스트 바이오사이언스 코포레이션 | 올리고핵산 변이체 라이브러리 및 그의 합성 |
| WO2017053450A1 (en) | 2015-09-22 | 2017-03-30 | Twist Bioscience Corporation | Flexible substrates for nucleic acid synthesis |
| EP4664304A3 (en) | 2016-09-21 | 2026-01-21 | Atlas Data Storage, Inc. | Nucleic acid based data storage |
| WO2018156792A1 (en) | 2017-02-22 | 2018-08-30 | Twist Bioscience Corporation | Nucleic acid based data storage |
| IL271205B2 (en) | 2017-06-12 | 2025-02-01 | Twist Bioscience Corp | Methods for assembling continuous nucleic acids |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| CN111566125A (zh) | 2017-09-11 | 2020-08-21 | 特韦斯特生物科学公司 | Gpcr结合蛋白及其合成 |
| CN111565834B (zh) | 2017-10-20 | 2022-08-26 | 特韦斯特生物科学公司 | 用于多核苷酸合成的加热的纳米孔 |
| IL312616B2 (en) | 2018-01-04 | 2025-08-01 | Twist Bioscience Corp | Dna-based digital information storage |
| EP3814497A4 (en) | 2018-05-18 | 2022-03-02 | Twist Bioscience Corporation | POLYNUCLEOTIDES, REAGENTS AND METHODS FOR NUCLEIC ACID HYBRIDIZATION |
| EP3902816A4 (en) | 2018-12-26 | 2022-09-14 | Twist Bioscience Corporation | HIGH-PRECISION DE NOVO POLYNUCLEOTIDE SYNTHESIS |
| CA3131689A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
| KR20210144698A (ko) | 2019-02-26 | 2021-11-30 | 트위스트 바이오사이언스 코포레이션 | 항체 최적화를 위한 변이 핵산 라이브러리 |
| PL3952858T3 (pl) * | 2019-04-12 | 2026-03-30 | QBiotics Pty Ltd | Sposób leczenia guzów |
| BR112021024716A2 (pt) * | 2019-06-19 | 2022-02-08 | QBiotics Pty Ltd | Ruptura de biofilme |
| EP3987019A4 (en) | 2019-06-21 | 2023-04-19 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| CN115023440B (zh) | 2019-09-23 | 2025-09-12 | 特韦斯特生物科学公司 | 结合CD3ε的抗体 |
| US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
| AU2020400030B2 (en) | 2019-12-09 | 2026-05-21 | Twist Bioscience Corporation | Variant nucleic acid libraries for adenosine receptors |
| WO2022159620A1 (en) | 2021-01-21 | 2022-07-28 | Twist Bioscience Corporation | Methods and compositions relating to adenosine receptors |
| KR102774792B1 (ko) | 2021-05-06 | 2025-03-05 | 한국과학기술연구원 | 가시광선에 의해 활성화되는 항암 면역치료용 나노입자 및 이의 용도 |
| CN118451065A (zh) * | 2021-12-21 | 2024-08-06 | Q生物股份有限公司 | 结晶中间体 |
| JP2025505797A (ja) * | 2022-02-17 | 2025-02-28 | キューバイオティクス プロプライアタリー リミティド | 併用療法 |
| EP4638430A4 (en) * | 2022-12-21 | 2026-07-01 | QBiotics Pty Ltd | CRYSTALLINE FORMS AND THEIR PRODUCTION PROCESSES |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007009055A2 (en) * | 2005-07-13 | 2007-01-18 | Salvia Sciences, Inc. | Ester prodrugs of prostratin and related phorbol compounds |
| DK1971588T3 (da) * | 2005-12-23 | 2012-10-22 | Qbiotics Ltd | Tiglien-3-onderivater |
| PT2986615T (pt) * | 2013-04-18 | 2019-03-22 | Qbiotics Ltd | Métodos e composições para a cicatrização de feridas |
| JP6501413B2 (ja) * | 2014-03-07 | 2019-04-17 | 国立大学法人京都大学 | 細胞培養用組成物 |
| ES2833425T3 (es) | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| CA2964155A1 (en) | 2014-10-10 | 2016-04-14 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonist with checkpoint inhibitors |
| CN104926758A (zh) * | 2015-05-22 | 2015-09-23 | 南京泽朗医药科技有限公司 | 斑籽素的制备方法及其在抗白血病药物中的应用 |
| AR105592A1 (es) * | 2015-08-03 | 2017-10-18 | Quadriga Biosciences Inc | b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS |
-
2018
- 2018-03-23 SG SG11201907891XA patent/SG11201907891XA/en unknown
- 2018-03-23 MY MYPI2019005163A patent/MY197427A/en unknown
- 2018-03-23 DK DK18770812.8T patent/DK3600281T3/da active
- 2018-03-23 HR HRP20230936TT patent/HRP20230936T1/hr unknown
- 2018-03-23 AU AU2018238202A patent/AU2018238202C1/en active Active
- 2018-03-23 SI SI201830978T patent/SI3600281T1/sl unknown
- 2018-03-23 KR KR1020197031149A patent/KR102228055B1/ko active Active
- 2018-03-23 ES ES18770812T patent/ES2953575T3/es active Active
- 2018-03-23 LT LTEPPCT/AU2018/050277T patent/LT3600281T/lt unknown
- 2018-03-23 FI FIEP18770812.8T patent/FI3600281T3/fi active
- 2018-03-23 UA UAA201910449A patent/UA125614C2/uk unknown
- 2018-03-23 RS RS20230697A patent/RS64472B1/sr unknown
- 2018-03-23 WO PCT/AU2018/050277 patent/WO2018170559A1/en not_active Ceased
- 2018-03-23 CN CN201880019617.4A patent/CN110461324A/zh active Pending
- 2018-03-23 PT PT187708128T patent/PT3600281T/pt unknown
- 2018-03-23 EA EA201992220A patent/EA201992220A1/ru unknown
- 2018-03-23 EP EP18770812.8A patent/EP3600281B1/en active Active
- 2018-03-23 CA CA3056685A patent/CA3056685C/en active Active
- 2018-03-23 SM SM20230272T patent/SMT202300272T1/it unknown
- 2018-03-23 MX MX2019011221A patent/MX391826B/es unknown
- 2018-03-23 HU HUE18770812A patent/HUE063299T2/hu unknown
- 2018-03-23 IL IL269522A patent/IL269522B2/en unknown
- 2018-03-23 JP JP2019552088A patent/JP6905075B2/ja active Active
- 2018-03-23 PL PL18770812.8T patent/PL3600281T3/pl unknown
- 2018-03-23 US US16/496,333 patent/US11213506B2/en active Active
-
2019
- 2019-09-11 ZA ZA2019/06001A patent/ZA201906001B/en unknown
- 2019-09-17 PH PH12019502132A patent/PH12019502132A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3600281B1 (en) | Combination therapy for the treatment or prevention of tumours | |
| Truxova et al. | Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma | |
| Grover et al. | Myeloid-derived suppressor cells: a propitious road to clinic | |
| Wu et al. | Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model | |
| Ochi et al. | Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans | |
| Li et al. | Small molecules as theranostic agents in cancer immunology | |
| CA3136216C (en) | Method of treating tumours | |
| Xia et al. | Angiogenic factors in chronic lymphocytic leukemia | |
| EP3400011A1 (en) | Anti-cd20 combinations for treating tumors | |
| Zuo et al. | A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer | |
| Ludwig et al. | Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma | |
| CN105744958B (zh) | 新颖医药组成物及其用途 | |
| HK40014624B (en) | Combination therapy for the treatment or prevention of tumours | |
| HK40014624A (en) | Combination therapy for the treatment or prevention of tumours | |
| Olgasi et al. | DNA vaccination against membrane-bound Kit ligand: a new approach to inhibiting tumour growth and angiogenesis | |
| BR112019019748B1 (pt) | Usos de um composto de epóxitigliano ou um sal farmaceuticamente aceitável do mesmo, usos de um inibidor do ponto de verificação imunológico e kit | |
| Liu et al. | Myeloid-derived suppressor cells promote therapy-induced resistance in prostate cancer | |
| EA044756B1 (ru) | Комбинированная терапия для лечения или предупреждения опухолей | |
| Miller et al. | Effects of a novel proteasome inhibitor, UR238 on the tumor immune microenvironment and growth in epithelial ovarian cancer | |
| HK40060616B (en) | Method of treating tumours | |
| HK40060616A (en) | Method of treating tumours |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220310 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250311 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250311 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250311 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260310 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260310 |